Chinese herbal medicines set off a wave of price increases, and the industry suggests multiple measures to break through

Since the beginning of this year, the prices of Chinese medicinal materials in China have begun to show a general upward trend.
The prices of 60% of Chinese medicinal materials have risen to varying degrees, and some medicinal materials have even increased by more than 100%
.
Among them, especially antiviral medicinal materials such as skullcap, Radix isatidis, Pinellia ternata, burdock seed, and Forsythia suspensae, are becoming very scarce while prices continue to rise
.
In this regard, industry analysts believe that the rising prices of Chinese medicinal materials have led to short supply.
On the one hand, it is affected by the epidemic and abnormal weather, and on the other hand, it is due to factors such as rising labor costs and the implementation of pharmacopoeias
.
Among them, it is worth mentioning that the impact of the epidemic on the prices of Chinese medicinal materials is very obvious
.
It is reported that the outbreak of the epidemic has further increased the public's recognition of Chinese medicine, and has also stimulated the demand for Chinese medicinal materials, which has promoted the price increase of some categories
.
For example, during the epidemic, the price of Forsythia rose from more than 50 yuan per kilogram to more than 70 yuan
.
Atractylodes macrocephala, Atractylodes macrocephala, Banlangen, etc.
also experienced different price increases
.
At present, a large number of Chinese medicine companies have been affected in the context of the continuous price increase of Chinese medicinal materials
.
It is understood that many traditional Chinese medicine companies mentioned this situation in this year’s semi-annual reports.
For example, the announcement disclosed by China Resources Sanjiu showed that “in the first half of 2021, due to the implementation of the 2020 version of the Pharmacopoeia and the impact of weather, some medicinal materials Prices have risen to a certain extent
.
The prices of series of medicinal materials such as frankincense and myrrh have risen in different ranges.
Forsythia is affected by the cold spring in the production areas, and the production has been reduced significantly, and the prices have fluctuated greatly
.
" There are also many pharmaceutical companies that have different downstream sales channels.
, Has also been affected to varying degrees
.
Some companies signed long-term contracts with hospitals at the beginning of the year and were unable to adjust prices based on the market, resulting in large losses
.
Some companies supplying pharmacies and pharmaceutical factories have increased the price of medicines according to market conditions.
While the price has been increased, sales have fallen to varying degrees, and profits have also decreased accordingly
.
In addition, many companies have also disclosed risk warnings, stating that due to the scarcity of wild resources, artificial planting is affected by factors such as the climate environment and planting area, the company may face risks such as insufficient supply of raw materials.

.
In this regard, the industry believes that, on the whole, the price increase of Chinese medicinal materials has become a long-term trend, and a new round of reshuffle of the industry affected by this may be about to strike
.
So, in the context of the general rise in the prices of Chinese medicinal materials, how should relevant companies respond? According to the industry, in the face of price increases, pharmaceutical companies can on the one hand strengthen their own market price monitoring and analysis, improve their forecasting capabilities, and carry out strategic reserve procurement of key raw materials to reduce procurement costs; on the other hand, they can also build bulk raw materials.
The procurement platform realizes centralized procurement of some raw and auxiliary materials and packaging materials, optimizes resources, and reduces the overall cost of the industrial chain
.
In addition, many people in the industry suggested that relevant companies can strengthen the connection and technical guidance with Chinese herbal medicine growers in terms of planting, and ensure the orderly development of the supply side of the herbal medicines and continuously improve the quality of Chinese herbal medicines to ensure qualified Chinese medicines.
The normal supply of materials
.